Abstract This report described the effi cacy of NA inhibitors against newly evolved strains of H1N1 viruses. This in silico study was designed to understand the mode of interactions of NA inhibitors with NA. Hence, ligand, oseltamivir, zanamivir and peramivir were docked with modeled NA, ACD65204 (USA/2007), BAA06717 (Japan/1992), ACE77988 (S. Korea/2005) and ACD65204 (USA/2007). This study is based on interaction energies. Ramachandran Z-scores for these modeled structures were found to be -0.998, -1.121, -0.870 and -1.023, respectively, which confi rms the accuracy of the modeled structures. These interactions revealed that some of these interacting residues have remained conserved throughout all the pandemics. These amino acid residues were found to be R118, R152, R225, E277, E278, R293 and Y402. Moreover, our study concludes that peramivir is the most effi cient inhibitor against NA of H1N1.
Introduction
A new H1N1 "swine" infl uenza virus was recently detected in individuals from the United States who presented respiratory symptoms, and the same virus was subsequently confi rmed in patients from several countries around the world [1] . Infl uenza virus is a typical enveloped [2] negative-strand RNA virus which is composed of eight single-stranded genomic segments coding for 10 or more polypeptides [3, 4] . Infl uenza pandemics arise from genetic reassortment between avian and human infl uenza viruses or alternatively by the direct adaptation of an avian infl uenza viruses to effi cient human-to-human transmission [5] .
Designing of potential antiviral drug candidates in order to control infl uenza epidemics and eventual pandemics are the area of priority research. The most potential target to design inhibitors is neuraminidase (NA). These inhibitors act upon the active site of enzyme and stop releasing the newly assembled virions from the host cells to further infect cells of respiratory mucus. Two available NA inhibitors, zanamivir and oseltamivir have been found effective against seasonal infl uenza virus infection [6] . More inhibitors are in the stage of development like pyrrolidine-based compound from Abbott laboratories (A 315675) showing in vitro activity similar to that of zanamivir and oseltamivir against different strains (N1, N2, N9 subtypes) of infl uenza A viruses and B viruses [7, 8] .
The emergence of drug-resistant variants is one of the disadvantages of antiviral therapy. There were reports on adamantine-resistant H1N1 and H3N2 infl uenza virus variants emerge just after treatment [9] . Moreover, zanamivir-resistant infl uenza virus variant have been isolated from only immunocompromised patients [10] Structural minimization of the whole complex was carried out until the fi nal root-mean square deviation became less than 0.1 kcal/mol/A°. The lowest-energy structures were selected as energy-refi ned complex models. The models were duly verifi ed by Procheck [14] and verify 3D programmes [15] . Discovery Studio 2.0 (Accelrys) was used to prepare Ramachandran plots for the modeled structures. Ramachandran Z-scores for the evaluation of these models were calculated using 'WHAT IF' package. Alignments were performed by 'clustalW'. data is available on the appearance of variants with H274Y or N294S NA amino acid substitutions in fi ve oseltamivirtreated patients with H5N1 infection [11, 12] . In view of the emerging problem of resistance against these inhibitors, we initiated to study the effi cacy of these available inhibitors against H1N1 strains in different regions of the world during different pandemics.
Materials and methods
BLAST-P was performed to retrieve suitable templates for homology modeling using the study NA sequences which were in turn obtained from the 'NCBI Infl uenza resource'. Protein Data Bank (PDB) IDs of the templates retrieved for Model from sequence BAA06717 (Japan/1992) and Peramivir 
Results and discussion
We report here the effi cacy of the available NA inhibitors against different strains of H1N1 virus. The rationale behind this study was to compare the emerging strains of H1N1 in different regions during different outbreaks for their resistance against antiviral therapy. The data was compared with the year of 1930 strain as an original strain. (Fig. 1) shows oseltamivir bound to neuraminidase (NA) modeled from sequence ACD65204 (USA/2007). Discovery Studio 2.0 analysis of the docked-complexes (Receptor: modeled NA; Ligand: Oseltamivir/Zanamivir/Peramivir) revealed that there are several amino acid residues which are crucial to the interaction between NA and NA-inhibitors (Fig. 2) . Moreover, it was observed that some of these interacting residues have remained conserved throughout all the pandemics. These amino acid residues were found to be R118, R152, R225, E277, E278, R293 and Y402. The It is noteworthy to mention that the choice of these NAsequences was totally random with respect to year and country of isolation. A striking fi nding was observed during the clustalW alignment of these sequences, compared with the most recent NA sequence reported from Canada in 2009 pandemic (Fig. 3) that, the amino acid residues R118, R152, R225, E277, E278, R293 and Y402 were conserved in the Canadian sequence (Accession No.-ACR01027).
Interaction energies for the docked-complexes calculated by Hex5.1 are summarized in Table 1 . A higher value of negative interaction energy is an indicator of more effi cient interaction between the enzyme (NA) and its inhibitor. In terms of interaction energies, the order of effi ciency for the study inhibitors against modeled NA sequences belonging to the years 1930, 1992 and 2005 was found as, peramivir (most effi cient) > zanamivir > oseltamivir (least effi cient). However, the trend for modeled NA sequence belonging to 2007 was found as, peramivir (most effi cient)> oseltamivir > zanamivir (least effi cient). A rise of resistance against oseltamivir in H1N1 viruses during 2007-2008 has been observed. Fifty seven of 896 infl uenza A (H1N1) strains had IC50 S against oseltamivir ranging from 85.08nM to 255.83nM and are classifi ed as extreme outliner [16] . Therefore, with such kind of data has become important to understand the molecular changes occurred in emerging strains H1N1 viruses.
Hence, Peramivir was found to be the overall most effi cient inhibitor. Table 2 shows bioinformative details of the modeled neuraminidase structures. Sequences having accession nos. as ABV25644, BAA06717, ACE77988 and ACD65204 possessed 94.8%, 88.3%, 89.6% and again 89.6% sequence identity to the protein sequence used as template for homology modeling (PDB ID: 3b7Eb). Ramachandran Z-scores for these modeled structures were found to be -0.998, -1.121, -0.870 and -1.023, respectively. This confi rms the accuracy of the modeled structures. Amino acid changes present in the NA sequences considering the (Japan/1992)  T3P, C14S, L15M, I16A, V17I, T20I, I34A, R41G, D42S, P46T, E47G, T48I, S52R, I53M, N59S, A72T,  I74V, Q78K, A80K, M83V, I84T, R96G, S101T, I114V, T157A, I163L, S189G, N200D, D214E, N221K,  K222Q, A232V, N248D, Q250P, K254R, R262K, I263V, I264T, N270D, S286G, K287T, D307N,  N329K, T332E, G336N, S349T, S340V, N341D, N334D, F351Y, I365N, S366R, S367L, S369K, E382D,  S386D, I393V, I396M, I418M, 
